NCCN 2021 Virtual Congress™: Breast Cancer with Updates from 2020 San Antonio Breast Cancer Symposium

Breast cancer continues to be the second most common cause of cancer death in women in the United States. Results from numerous clinical trials continue to expand diagnostic/prognostic tools, therapeutic options, and supportive care strategies.

HER2-Positive Breast Cancer: A Guide Through An Evolving Treatment Landscape

The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for their patients with HER2-positive breast cancer.

 

Recorded Presentation from the NCCN Pharmacy Updates: New Targets in Breast Cancer Therapy
Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practices remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which we already have agents or are currently developing agents.
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer
Staying up-to-date with the available treatment options is important for health care professionals to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profile is important to optimize patient outcomes.
NCCN Pharmacy Updates: New Targets in Breast Cancer Therapy
Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practices remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which we already have agents or are currently developing agents.
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer
Staying up-to-date with the available treatment options is important for health care professionals to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profile is important to optimize patient outcomes.
Management of Metastatic Breast Cancer
The decision-making process for metastatic breast cancer involves a detailed discussion with patients of the benefits and risks associated with all possible treatment strategies. With expanding treatment options, clinicians need to understand important criteria used in picking optimal first-and subsequent line therapies for individuals with metastatic breast cancer and also have a knowledge of the biomarkers that should be tested to guide therapeutic decisions in patients with metastatic breast cancer. 
Locoregional Management of Early-Stage Breast Cancer

Locoregional management strategies have considerably evolved.

Current Insights: Evolving Principles and Controversies of Cancer Risk Assessment and Management of Hereditary Cancers

There is currently a lack of evidence regarding proper procedures and risk management strategies that should follow multi-gene testing, especially when pathogenic or likely pathogenic variants are found for moderate-penetrance genes and when a variant of unknown significance (VUS) is found.

Management of Toxicities with Targeted Therapies for Breast Cancer
Staying up-to-date with the available treatment options is important to clinicians integrating new evidence-based data into their clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.

Pages

Subscribe to RSS - Breast Cancer